Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of YYC301 in Knee Osteoarthritis
NCT05362851Phase 3Unknown
- Sponsor
- Yooyoung Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of YYC301 + celecoxib in osteoarthritis (OA) (4 arms), sponsored by Yooyoung Pharmaceutical. Primary endpoint: Visual Analog Scale for Pain at 13 weeks. Status: unknown.
02
Drugs
YYC301 + celecoxib
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05362851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362851.